FINWIRES · TerminalLIVE
FINWIRES

調査速報:CFRAはカーライル・カンパニーズ・インコーポレイテッドの株式について買い推奨を維持

By

-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。2027年のPERを18.4倍と想定し、12ヶ月目標株価を417ドルから440ドルに引き上げます。これは、過去10年間の平均予想PERとほぼ一致しています。また、2026年の調整後EPS予想を21.12ドルから21.15ドルに、2027年の調整後EPS予想を23.85ドルから23.90ドルにそれぞれ引き上げます。CSLの第1四半期調整後EPSは3.63ドル(前年同期比1%増)となり、市場予想の3.34ドルを大きく上回りました。この四半期は、予想を上回る利益率が特徴で、売上高は4%減の10億5000万ドル(市場予想を1100万ドル下回る)となり、調整後EBITマージンは30ベーシスポイント拡大して17.1%(市場予想を100ベーシスポイント上回る)となった。CSL株は木曜日の発表後、7%上昇した。我々の見解では、最大のプラス要因は、売上高が5%減少したにもかかわらず、CCMセグメント(四半期総売上高の約72%)の利益率が拡大したことである。Vision 2030の下で経営陣が40ドルEPSを目指す道は、有機的成長、利益率拡大の可能性、および加速するイノベーションパイプラインによって達成可能だと考えている。優れたキャッシュフロー、強固なバランスシート、および株主への強力な還元が、我々の「買い」の見方を支えている。

Related Articles

Asia

Biocytogen Pharmaceuticals Turns to Profit in Q1

Biocytogen Pharmaceuticals (Beijing) (HKG:2315) recorded an attributable profit of 104 million yuan in the first quarter of 2026, compared with an attributable loss of 13.2 million yuan a year prior, according to a Monday Hong Kong bourse filing.Earnings per share stood at 0.23 yuan, compared with a loss per share of 0.03 yuan in the corresponding period of the previous fiscal year.Operating revenue jumped 74% in the three months to 433.1 million yuan from 249.3 million yuan in the year-ago period, driven by a substantially higher revenue contribution from pharmacology and efficacy services and animal models.The pharmaceutical company attributed the higher profit mainly to revenue growth and improved operating efficiency amid expense management.

$HKG:2315
Oil & Energy

Market Chatter: LNG Carrier Orders Surge as Global Output Defies Iran War Tensions

Global demand for liquefied natural gas carriers is rebounding sharply in 2026, despite the ongoing US-Iran conflict, Reuters reported Monday, citing analysts and industry experts.Analysts report that surging LNG production and a transition toward high-efficiency vessels are fueling the recovery.According to the report, Shipbuilders in South Korea and China have already secured 35 new build contracts in Q1 alone.The resurgence in construction comes despite the escalating US-Iran war, which has choked the Strait of Hormuz and raised fears of a prolonged shipping downturn.However, market experts suggest that the need for modern, fuel-efficient tonnage is outweighing immediate freight rate concerns, it said.These new vessels, which cost between $250 million and $260 million and take over three years to complete, are increasingly necessary as older, steam-propelled tankers are scrapped at record rates to meet stricter global emissions regulations.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Research

Canaccord Genuity Initiates Coverage on Structure Therapeutics With Buy Rating, $101 Price Target

Structure Therapeutics (GPCR) has an average rating of Buy and mean price target of $108.50, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$GPCR